Scarica l'app Stockscreener
42.20
0.82%
-0.35
Pre-mercato:
42.38
0.18
+0.43%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MRNA Giù?
Forum
Previsione
Precedente Chiudi:
$42.55
Aprire:
$42.65
Volume 24 ore:
9.36M
Relative Volume:
0.76
Capitalizzazione di mercato:
$16.49B
Reddito:
$3.14B
Utile/perdita netta:
$-3.36B
Rapporto P/E:
-4.8339
EPS:
-8.73
Flusso di cassa netto:
$-4.03B
1 W Prestazione:
-7.15%
1M Prestazione:
+36.75%
6M Prestazione:
+52.87%
1 anno Prestazione:
+15.46%
Intervallo 1D:
$41.28
$44.17
Intervallo di 1 settimana:
$41.28
$47.85
Portata 52W:
$22.28
$55.20
Moderna Inc Stock (MRNA) Company Profile
Nome
Moderna Inc
Settore
Industria
Telefono
(617) 714-6500
Indirizzo
325 BINNEY STREET, CAMBRIDGE
Confronta MRNA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
42.20 | 16.63B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.61 | 119.76B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
759.18 | 79.35B | 14.34B | 4.50B | 3.88B | 41.57 |
|
ARGX
Argen X Se Adr
|
851.72 | 51.71B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
351.80 | 44.80B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.38 | 38.18B | 4.98B | 69.60M | 525.67M | 0.5198 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-28 | Ripresa | Barclays | Equal Weight |
| 2026-01-07 | Ripresa | UBS | Neutral |
| 2025-12-12 | Iniziato | Jefferies | Hold |
| 2025-03-13 | Iniziato | Citigroup | Neutral |
| 2025-02-18 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-01-29 | Downgrade | Goldman | Buy → Neutral |
| 2024-12-18 | Downgrade | Argus | Buy → Hold |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-19 | Iniziato | Berenberg | Hold |
| 2024-11-18 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-09-13 | Downgrade | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Downgrade | Jefferies | Buy → Hold |
| 2024-09-13 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Downgrade | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Iniziato | Canaccord Genuity | Hold |
| 2023-11-03 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Downgrade | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Iniziato | William Blair | Mkt Perform |
| 2023-07-14 | Iniziato | HSBC Securities | Reduce |
| 2023-06-26 | Aggiornamento | UBS | Neutral → Buy |
| 2023-04-26 | Iniziato | Guggenheim | Neutral |
| 2023-03-13 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-02-24 | Downgrade | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-12-14 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Aggiornamento | Redburn | Sell → Neutral |
| 2022-01-26 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Iniziato | UBS | Neutral |
| 2021-12-07 | Iniziato | Cowen | Market Perform |
| 2021-11-09 | Iniziato | Wolfe Research | Outperform |
| 2021-10-22 | Iniziato | Deutsche Bank | Sell |
| 2021-10-15 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Reiterato | Jefferies | Hold |
| 2021-02-01 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Downgrade | Jefferies | Buy → Hold |
| 2020-12-16 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Downgrade | Needham | Buy → Hold |
| 2020-11-23 | Iniziato | Wells Fargo | Equal Weight |
| 2020-11-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-07-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Iniziato | Jefferies | Buy |
| 2020-06-30 | Iniziato | Argus | Buy |
| 2020-06-08 | Iniziato | Barclays | Overweight |
| 2020-04-30 | Iniziato | BMO Capital Markets | Outperform |
| 2020-03-05 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Ripresa | BofA/Merrill | Buy |
| 2019-10-25 | Iniziato | ROTH Capital | Buy |
| 2019-04-05 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Moderna Inc Borsa (MRNA) Ultime notizie
PATENT—D. Del.: Most COVID-19... - VitalLaw.com
Moderna's 7-Step Guide to Veeva AI for PromoMats - Veeva
Why The Narrative Around Moderna (MRNA) Is Shifting After Mixed Analyst Updates - Yahoo Finance Singapore
Moderna Refocuses On Rare Disease Pipeline As Leadership Evolves - Yahoo Finance
Palmetto Grain Brokerage - Palmetto Grain Brokerage
Are Wall Street Analysts Bullish on Moderna Stock? - FinancialContent
How Moderna Uses Decision Intelligence to Enable an Autonomous Cold Chain, Upcoming Webinar Hosted by Xtalks - Yahoo Finance
BioNTech Expands Beyond mRNA While Moderna Focuses on mRNA Pipeline Post-Pandemic - geneonline.com
'Star Trek'-Citing Judge Says Moderna Can't Ax $5B Vax IP Suit - Law360
Moderna Again Fails to Shift Most Covid-Shot Patent Costs to US - Bloomberg Law News
Moderna (MRNA) Stock Falls Amid Market Uptick: What Investors Need to Know - Nasdaq
Moderna (MRNA) Sees Moderate Bearish Activity Amid Upcoming Earnings - GuruFocus
Patent Ruling Update Affects Arbutus Biopharma (ABUS) in Legal B - GuruFocus
Arbutus Biopharma (ABUS) Patent Dispute Over COVID-19 Vaccine De - GuruFocus
Arbutus jumps on ruling in patent dispute with Moderna (ABUS:NASDAQ) - Seeking Alpha
Jim Cramer on Moderna: “We have to wait and see” - MSN
Spotlight on Moderna: Analyzing the Surge in Options Activity - Benzinga
Moderna, Inc.'s (NASDAQ:MRNA) Price Is Right But Growth Is Lacking After Shares Rocket 43% - simplywall.st
Moderna Refocuses On Rare Diseases As New Leadership Shapes Pipeline - Yahoo Finance
Is Moderna (MRNA) Pricing Fair After Recent 42.8% Monthly Share Price Jump - Yahoo Finance
Gainers Report: Can Moderna Inc continue delivering strong returnsIndex Update & Precise Swing Trade Entry Alerts - baoquankhu1.vn
Moderna Stock Slips As Ambitious Cancer Trials Drag On - TipRanks
91,010 Shares in Moderna, Inc. $MRNA Purchased by Mitsubishi UFJ Trust & Banking Corp - MarketBeat
Privium Fund Management B.V. Lowers Holdings in Moderna, Inc. $MRNA - MarketBeat
Moderna Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference - Hattiesburg American
Moderna appoints David Berman as new chief development officer By Investing.com - Investing.com South Africa
Moderna: Analyzing The January Rally And The Road Ahead (Rating Upgrade) (NASDAQ:MRNA) - Seeking Alpha
Moderna (MRNA) Announces Leadership Changes Amid Strategic Shift - GuruFocus
Moderna CMO Jacqueline Miller to step down - WKZO
Moderna announces departure of medical chief (MRNA:NASDAQ) - Seeking Alpha
Leerink Partners Adjusts Moderna Price Target to $17 From $18, Maintains Underperform Rating - marketscreener.com
Moderna, Inc. Announces Executive and Committee Changes, Effective March 2, 2026 - marketscreener.com
Moderna Vs. Novavax: 2 Pandemic Vaccine PioneersWhich Offers Better Value Today? (MRNA) - Seeking Alpha
Dr. David Berman to Join Moderna as Chief Development Officer - USA Today
Moderna Teams With Recordati on Rare Disease mRNA Therapy for up to $160M - BioSpace
Moderna appoints David Berman as new chief development officer - Investing.com
Immunotherapy veteran David Berman to steer drug development at Moderna - Stock Titan
Moderna, Inc. $MRNA Stock Holdings Reduced by Universal Beteiligungs und Servicegesellschaft mbH - MarketBeat
Moderna Announces Strategic Collaboration with Recordati to Globally Commercialize Investigational Propionic Acidemia Therapeutic (mRNA-3927) - The Desert Sun
Recordati partners with Moderna on rare disease treatment By Investing.com - Investing.com Canada
Recordati and Moderna Sign Global Agreement on mRNA Therapy for Rare Disease - marketscreener.com
Moderna (MRNA) Partners with Recordati for mRNA-3927 Development and Marketing - GuruFocus
Moderna Collaborates With Recordati to Advance, Commercialize Investigational Therapy to Treat Metabolic Disorder - marketscreener.com
Recordati Announces Collaboration With Moderna For Mrna-3927 - TradingView
RECORDATI ANNOUNCES STRATEGIC COLLABORATION WITH MODERNA TO DEVELOP AND COMMERCIALIZE WORLDWIDE mRNA 3927 FOR THE TREATMENT OF PROPIONIC ACIDEMIA - marketscreener.com
Moderna partners with Recordati on rare disease therapy - Investing.com
RecordatiAnnounces Collaboration With Moderna For Mrna-3927 - TradingView
Rare metabolic disease drug mRNA-3927 draws up to $160M Moderna-Recordati pact - Stock Titan
U.S. vaccine hesitancy could impact investment - Axios
Moderna Rethinks Late Stage Vaccine Funding And Investor Risk Balance - Yahoo Finance
Jim Cramer on Moderna: "We Have to Wait and See" - Finviz
Moderna Inc Azioni (MRNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.22%
2.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):